MYOS (NASDAQ:MYOS) Rating Lowered to Sell at ValuEngine

MYOS (NASDAQ:MYOS) was downgraded by equities researchers at ValuEngine from a “hold” rating to a “sell” rating in a research report issued on Monday, ValuEngine reports.

MYOS traded down $0.04 during trading on Monday, hitting $1.41. 19,281 shares of the stock were exchanged, compared to its average volume of 34,016. The firm has a market capitalization of $13.30 million, a P/E ratio of -3.13 and a beta of 0.80. MYOS has a 1-year low of $1.04 and a 1-year high of $2.02. The stock has a fifty day moving average price of $1.50 and a two-hundred day moving average price of $1.47. The company has a quick ratio of 1.21, a current ratio of 2.74 and a debt-to-equity ratio of 0.05.

MYOS (NASDAQ:MYOS) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The firm had revenue of $0.15 million for the quarter, compared to analyst estimates of $0.14 million. MYOS had a negative return on equity of 93.90% and a negative net margin of 603.47%. Analysts predict that MYOS will post -0.5 EPS for the current year.

An institutional investor recently raised its position in MYOS stock. Community Capital Management Inc. boosted its position in shares of MYOS Co. (NASDAQ:MYOS) by 295.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 142,452 shares of the company’s stock after buying an additional 106,392 shares during the period. Community Capital Management Inc. owned 1.55% of MYOS worth $217,000 as of its most recent SEC filing. 5.94% of the stock is owned by hedge funds and other institutional investors.

MYOS Company Profile

MYOS RENS Technology Inc, a bionutrition and biotherapeutics company, focuses on the discovery, development, and commercialization of nutritional and therapeutic products for maintaining and enhancing the health and performance of muscle tissue. The company primarily focuses on developing the products that enhance muscle health and function essential to the management of sarcopenia, cachexia, and degenerative muscle diseases, and as an adjunct to the treatment of obesity.

See Also: Economic Reports

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for MYOS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MYOS and related companies with's FREE daily email newsletter.